Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 314 participants.
Also called NCT01709513
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 314 participants
- Sponsor
- Registry
-
NCT01709513
-
- Other papers using this trial's data
- Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial
- Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Canada, France, Israel, Italy, Norway, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01709513. Randomized; quadruple masking; primary purpose treatment. Start 2012-09-30 (actual); primary completion 2014-05-31 (actual). Results posted on 2015-08-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct01709513- Content hash
da8b4cd989c7744a719ac84cebee76d870f164e035e247558cb271f89c4522b2